News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
783,371 Results
Type
Article (78357)
Company Profile (323)
Press Release (704691)
Section
Business (216705)
Career Advice (3512)
Deals (38063)
Drug Delivery (120)
Drug Development (89269)
Employer Resources (183)
FDA (17737)
Job Trends (16507)
News (374235)
Policy (37386)
Tag
Academia (2966)
Alliances (54769)
Alzheimer's disease (1365)
Approvals (17660)
Artificial intelligence (171)
Bankruptcy (366)
Best Places to Work (12410)
Biotechnology (219)
Breast cancer (200)
Cancer (1467)
Cardiovascular disease (125)
Career advice (2979)
CAR-T (109)
Cell therapy (323)
Clinical research (70888)
Collaboration (526)
Compensation (245)
COVID-19 (2799)
C-suite (121)
Data (1429)
Diabetes (190)
Diagnostics (6642)
Earnings (83693)
Employer resources (160)
Events (119066)
Executive appointments (414)
FDA (18444)
Funding (457)
Gene therapy (221)
GLP-1 (710)
Government (4997)
Healthcare (20482)
Infectious disease (2898)
Inflammatory bowel disease (125)
Interviews (666)
IPO (17170)
Job creations (4537)
Job search strategy (2474)
Layoffs (488)
Legal (9039)
Lung cancer (218)
Manufacturing (232)
Medical device (14152)
Medtech (14157)
Mergers & acquisitions (21057)
Metabolic disorders (522)
Neuroscience (1722)
NextGen Class of 2024 (7358)
Non-profit (5045)
Northern California (1710)
Obesity (295)
Opinion (249)
Patents (125)
People (62672)
Phase I (21845)
Phase II (30859)
Phase III (23231)
Pipeline (532)
Postmarket research (3394)
Preclinical (9802)
Radiopharmaceuticals (258)
Rare diseases (290)
Real estate (6901)
Regulatory (24929)
Research institute (2630)
Resumes & cover letters (550)
Southern California (1492)
Startups (3923)
United States (15763)
Vaccines (662)
Weight loss (231)
Date
Last 7 days (631)
Last 30 days (2481)
Last 365 days (37088)
2024 (36918)
2023 (42001)
2022 (53298)
2021 (58163)
2020 (57161)
2019 (50812)
2018 (38702)
2017 (36054)
2016 (36420)
2015 (42560)
2014 (36805)
2013 (33295)
2012 (34904)
2011 (34939)
2010 (34738)
Location
Africa (1144)
Arizona (201)
Asia (46635)
Australia (8192)
California (3886)
Canada (1462)
China (321)
Colorado (178)
Connecticut (193)
Europe (107520)
Florida (540)
Georgia (144)
Illinois (450)
Indiana (232)
Maryland (652)
Massachusetts (3062)
Michigan (185)
Minnesota (304)
New Jersey (1143)
New York (1110)
North Carolina (845)
Northern California (1710)
Ohio (153)
Pennsylvania (914)
South America (1504)
Southern California (1492)
Texas (570)
Utah (116)
Washington State (413)
783,371 Results for "european organization for research and treatment of cancer".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
News
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference
October 7, 2024
·
15 min read
Press Releases
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
November 18, 2024
·
13 min read
Biotech Beach
City of Hope Researchers to Present Investigational Treatments for Colorectal, Kidney and Blood Cancers at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
World-renowned physicians and researchers from City of Hope®, one of the largest cancer research and treatment organizations in the United States, will present new data and offer expert perspectives on leading-edge cancer research and treatments in development at the 2024 ASCO Annual Meeting.
May 23, 2024
·
11 min read
Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office
Propanc Biopharma, Inc. today announced that a certificate of grant for the Company’s “composition of proenzymes for cancer treatment,” patent was received from the European Patent Office.
April 16, 2024
·
3 min read
Press Releases
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
November 27, 2024
·
9 min read
Press Releases
BostonGene Unveils Transformative Breast Cancer Research at 2024 San Antonio Breast Cancer Symposium, Showcasing Precision Tools for Tailored Treatment Approaches
December 10, 2024
·
3 min read
Press Releases
Congruence and Ono Announce Multi-Target Research Collaboration to Generate Small Molecule Correctors for the Treatment of Cancer
December 4, 2024
·
3 min read
Press Releases
Adaptive Research Welcomes Western Radiation Oncology to Expand Community Access to Pioneering Cancer Treatment Trials
December 4, 2024
·
2 min read
Policy
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BeiGene, Ltd., a global oncology company, announced that the European Commission has approved tislelizumab as a treatment for non-small cell lung cancer across three indications, including first- and second-line use.
April 23, 2024
·
8 min read
Astellas’ XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the European Commission (EC) has approved a label extension for XTANDI™ (enzalutamide) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage-radiotherapy.
April 23, 2024
·
11 min read
1 of 78,338
Next
